Brugada syndrome (BrS) is a heritable disease that results in sudden cardiac death. In the exome/genomic era, certain reported pathogenic variants in some genetic diseases have been reclassified as benign owing to their high frequency in some ancestries. In the present study, we comprehensively reassessed all previously reported pathogenic variants of BrS. We collected all pathogenic variants of BrS reported in the Human Gene Mutation Database and ClinVar throughout April 2017. We compared the minor allele frequency (MAF) of each variant among different ancestries by searching public whole-genome and exome databases. After considering the maximum credible allele frequency, variants with a MAF ≥ 0.001 were considered to be of questionable pathogenicity. We also investigated the percentage of SCN5A variants with a MAF ≥ 0.001 in 124 BrS patients from the Han Chinese population. We collected a total of 440 BrS variants, of which 18 had a MAF ≥ 0.001. There was a greater percentage of non-SCN5A variants with a MAF ≥ 0.001 than of SCN5A variants (21.8 versus 1.6%, < 0.0001). There were fewer frameshift and nonsense mutations than missense mutations (0.9 versus 5.6%, = 0.032). Of the 18 variants, 14 (77.8%) were present only in the reference Asian population. In our cohort, we identified two SCN5A variants (p.A226V and p.V1340I) with MAFs ≥ 0.001 (0.45%). In conclusion, ancestral differences are important when considering the pathogenicity of BrS variants, especially in the case of missense variants and non- variants, which may be pathogenic in some ancestries but only disease-predisposing in others.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328444 | PMC |
http://dx.doi.org/10.3389/fgene.2018.00680 | DOI Listing |
Pol J Radiol
November 2024
Department of Surgery, Section of Vascular Surgery and Endovascular Therapy, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
Purpose: Monocyte chemoattractant protein-1 (MCP-1/CCL2) plays a key role for infiltration of monocytes/macrophages and studies have demonstrated that the MCP-1/C-C chemokine receptor 2 (CCR2) axis might be involved in the pathogenesis and progression of abdominal aortic aneurysms (AAA). Molecular imaging has shown potential for human clinical research studies. We evaluated the expression of CCR2 in patients with small AAA using single-photon emission computed tomography (SPECT) with the technetium-99m-6-hydrazinylnicotinoyl-C-C-chemokine receptor-2 ligand (Tc-HYNIC-CCR2-L).
View Article and Find Full Text PDFBackground And Aims: An arterial aneurysm is characterized by a localized expansion of a blood vessel relative to its original dimensions. Specifically, an abdominal aortic aneurysm (AAA) is identified as an aortic diameter measuring at least one and a half times the standard diameter at the renal artery level, approximately equivalent to 2.0 cm.
View Article and Find Full Text PDFPhys Med Biol
January 2025
Vanderbilt University Medical Center, 1161 21st Ave. S, Medical Center North, AAA-3112, Nashville, Tennessee, 37232-2102, UNITED STATES.
Objective: A new nuclear Overhauser enhancement (NOE)-mediated saturation transfer MRI signal at -1.6 ppm, potentially from choline phospholipids and termed NOE(-1.6), has been reported in biological tissues at high magnetic fields.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Dompé Farmaceutici S.p.A., Via Campo di Pile, Nucleo Industriale Pile, 67100 L'Aquila, Italy.
Thus far, no manufacturing process able to support industrialization has been reported for the recombinant human brain-derived neurotrophic factor (rhBDNF). Here, we described the setup of a new protocol for its production in () and its purification to homogeneity. A synthetic gene, codifying for the neurotrophin precursor, was inserted into an expression vector and transformed into BL21 (DE3) strain.
View Article and Find Full Text PDFBiomedicines
December 2024
Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Background: Adalimumab, an anti-TNF-α biologic agent, has emerged as a principal treatment option for patients with non-infectious uveitis. The influence of adalimumab anti-drug antibodies (AAA) on the efficacy of adalimumab therapy is not yet fully understood. We aim to understand their clinical implications in the context of therapeutic drug monitoring and the factors contributing to the formation of these antibodies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!